Product Details

Spartalizumab biosimilar is a humanized IgG4 monoclonal antibody targeting PD-1, a protein on T cells involved in immune regulation. It works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby preventing the inhibitory signals that usually suppress T-cell activation. This action leads to the activation of T cells and the stimulation of immune responses, making it useful for cancer immunotherapy. As a research-grade biosimilar, Spartalizumab is not intended for therapeutic use but is available for applications such as ELISA, neutralization assays, and bioanalytical assays.